Company / Revenue per Share
Tvardi Therapeutics, Inc. Revenue per Share History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$9.22
FY2024
5-year range
$0.29 / $9.22
FY2020-FY2024
Trend
+2054.3%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue per Share changed +2054% YoY in FY2024, a notable deviation from the 9-year average annual change of +479%.
Based on SEC 10-K filings.
9.22 in FY2024 with a 5-year CAGR of +231.5%.
Improved from $2.53 to $9.22 over the past 2 years.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- +184.9%
- 5-Year CAGR
- +231.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, revenue per share increased 2054.3% year-over-year.
- Lowest revenue per share in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -6.41 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $9.22 | +2054.3% |
| FY2023 | $0.43 | -83.1% |
| FY2022 | $2.53 | +533.4% |
| FY2021 | $0.40 | +38.3% |
| FY2020 | $0.29 | +1151.5% |
| FY2019 | $0.02 | +774.9% |
| FY2018 | $0.00 | -98.1% |
| FY2017 | $0.14 | +19.5% |
| FY2016 | $0.12 | -77.8% |
| FY2015 | $0.52 | +89.1% |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026